Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with Azacitidine and Venetoclax in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.


Clinical Trial Description

The dual treatment, VENETOCLAX and AZACITIDINE, is the standard of care for patients with newly diagnosed AML who are ineligible for intensive chemotherapy. However, upfront resistance as well as relapse following initial response demonstrate the need to improve this therapeutic strategy. NP137 is a first-in-class humanized monoclonal antibody targeting specifically and selectively Netrin-1. Based on data collected from non clinical studies NP137 should act in synergy with VENETOCLAX and AZACITIDINE to reactivate and enhance the apoptotic pathway in AML cells. The herein proposed study to assess the safety (Safety run in/ phase I part) and the preliminary efficacy signal (extension phase II part) of the NP137 when combined to AZACITIDINE AND VENETOCLAX in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax. This study will be an open-label, Phase I/II trial. the first part, consists to a safety run to assess the security and the tolerability of the drugs combination from the first 6 to 12 first patients enrolled into the study. All patients will receive a fixed dose of NP137 at the RP2D (Recommended Phase 2 Dose) determined from the First in human NP137 study(DL1) . A dose deescalation of NP137 is planned to DL-1 according to the Dose Limiting Toxicities observed during this period. The second part will be will be then conducted as a phase II using an adaptive Bayesian approach allowing to quickly stop treatment without evidence of efficacy. The clinical activity will be assessed based on ELN (European LeukemiaNet) criteria 2027 for the Acute Myeloid Leukemia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06150040
Study type Interventional
Source Centre Leon Berard
Contact Anne-Sophie MICHALET, MD
Phone 4 78 78 26 41
Email anne-sophie.michallet@lyon.unicancer.fr
Status Recruiting
Phase Phase 1/Phase 2
Start date December 4, 2023
Completion date November 30, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05574608 - Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia Early Phase 1
Recruiting NCT06125652 - Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) Phase 1/Phase 2
Recruiting NCT05105152 - PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Phase 1
Recruiting NCT05546580 - Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Phase 1
Recruiting NCT05317403 - Venetoclax to Augment Epigenetic Modification and Chemotherapy Phase 1
Recruiting NCT05211570 - AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT03690154 - A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML Phase 1
Not yet recruiting NCT05854966 - CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Not yet recruiting NCT06459024 - Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Recruiting NCT05506332 - Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05949125 - Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 Phase 1
Recruiting NCT06128044 - CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT06281847 - An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia Phase 1/Phase 2
Recruiting NCT06201247 - Off-the-shelf CD123 CAR-NK for R/R AML Early Phase 1
Recruiting NCT04347616 - Natural Killer-cell Therapy for Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT04914845 - KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT06017258 - A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia Phase 1
Recruiting NCT05190471 - A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT06297941 - Study of REM-422 in Patients With AML or Higher Risk MDS Phase 1
Not yet recruiting NCT06372717 - A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS Phase 1/Phase 2